Editorial Comment: A Simplified Prediction Tool for Metastasis after Nephrectomy with Venous Tumor Thrombectomy for RCC

Renal cell carcinoma (RCC) exhibits propensity to form venous tumor thrombus (VTT) in approximately 10-15 percent of cases. 1 Despite recent advances in systemic immunotherapy regimens, surgical excision remains the standard of care and is curative in approximately half of patients presenting with VTT. Prior clinical work has validated the use of clinical variables for predicting progression-free and cancer-specific survival in patients undergoing nephrectomy for all RCC subtypes. 2,3 However, challenges remain in identifying patients who will subsequently develop metastatic recurrence. Roberson et al . address prognostication in a population diagnosed with non-metastatic renal cell carcinoma (RCC) and venous tumor thrombus (VTT) undergoing extirpative surgery. 4 Risk stratification and 5-year metastasis-free survival (MFS) in this group is increasingly important given the recent introduction of effective adjuvant immunotherapy following nephrectomy for RCC. 5 In KEYNOTE-5644, adjuvant pembrolizumab improved MFS and overall survival following nephrectomy in patients with high-risk RCC, yet nearly half of patients would be overtreated, signaling the need for refined risk stratification techniques.